Caris Life Sciences, Inc.
CAI
$18.26
-$0.21-1.14%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 236.92% | 133.88% | 30.02% | -177.64% | 45.45% |
| Total Depreciation and Amortization | -11.89% | -24.01% | -9.03% | -22.29% | -13.92% |
| Total Amortization of Deferred Charges | -75.44% | -68.24% | 298.71% | 2.05% | 4.38% |
| Total Other Non-Cash Items | 2.06% | -74.86% | 35.60% | 918.53% | -318.02% |
| Change in Net Operating Assets | -519.51% | 1,078.94% | -110.80% | 291.17% | 58.52% |
| Cash from Operations | -28.27% | 756.55% | 123.26% | 19.48% | 43.94% |
| Capital Expenditure | 28.26% | -411.90% | 48.46% | -17.42% | -25.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 28.26% | -411.90% | 48.46% | -17.42% | -25.27% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -69.57% | -4.55% | 0.00% | -4.76% | 19.23% |
| Issuance of Common Stock | 235.53% | -99.78% | 36,835.08% | 427.21% | -58.47% |
| Repurchase of Common Stock | 97.44% | -898.79% | -7,436.36% | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -230.83% | 4,223.81% | -320.00% | 95.39% |
| Cash from Financing | 116.11% | -103.10% | 52,927.39% | 468.58% | 159.77% |
| Foreign Exchange rate Adjustments | -146.77% | -33.33% | 2,225.00% | 500.00% | 93.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.56% | -95.01% | 2,199.69% | 20.12% | 42.42% |